Related Experiment Video
Updated: Jan 18, 2026

Nitropeptide Profiling and Identification Illustrated by Angiotensin II
Published on: June 16, 2019
Tunable Biased Signaling of the Angiotensin II Type 1 Receptor for Inotropy via C-Terminal Peptide Engineering and
Margot Hadjadj1,2,3, Malihe Hassanzadeh1,3, Justin Martel1,2,3
1Département de Pharmacologie-Physiologie, Faculté de Médecine et des Sciences de la Santé, Centre de Recherche du CHUS, Université de Sherbrooke, Sherbrooke, Québec J1H 5N4, Canada.
Abstract:
The angiotensin II (AngII) type 1 receptor (AT1R) is a key prototypical G protein-coupled receptor in cardiovascular regulation. Biased agonists activating G protein or β-arrestin pathways offer therapeutic promise, but the molecular determinants of this signaling bias and its physiological implications remain poorly understood. This study profiles AngII analogs with C-terminal Phe8 modifications, identifies compounds 11, 12, and 29a as exhibiting differential Gαq activation while retaining potent β-arrestin recruitment. Notably, 12 with low levels of Gαq activity, enhances left ventricular ejection fraction with limited pressor responses in normotensive rats. In contrast, other analogs with variably superior Gαq activity do not promote inotropy. Molecular modeling suggests that the flexible side chain of 12 accesses a deep allosteric pocket within AT1R, driving its unique signaling profile. This study demonstrates that engineering AngII's C-terminus enables selective tuning of AT1R signaling to control arterial versus cardiac responses, providing strategies for developing improved cardiovascular therapeutics.
Related Concept Videos
Transducer Mechanism: Enzyme-Linked Receptors
Major types that are helpful drug targets include:
Antihypertensive Drugs: Angiotensin II Receptor Blockers
Heart Failure Drugs: Inhibitors of Renin-Angiotensin System
Antihypertensive Drugs: Angiotensin-Converting Enzyme Inhibitors
Allosteric Regulation
Antihypertensive Drugs: Direct Renin Inhibitors

